Investor Reports 0.3% Stake in Calidi Biotherapeutics
Ognian Anguelov Gavrilov filed a Schedule 13D updating his ownership in Calidi Biotherapeutics, Inc. common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
SCHEDULE 13D
Rhea-AI Filing Summary
Ognian Anguelov Gavrilov filed a Schedule 13D updating his ownership in Calidi Biotherapeutics, Inc. common stock. He now beneficially owns 20,000 shares, representing 0.3% of the outstanding shares, with sole voting and dispositive power over this amount.
The filing notes this follows dispositions of shares and states he currently has no specific plans for corporate actions involving Calidi, though he may buy or sell shares in the future based on market conditions.
Key Figures
Beneficial ownership: 20,000 shares
Percent of class owned: 0.3%
Sole voting power: 20,000 shares
+2 more
5 metrics
Beneficial ownership
20,000 shares
Common Stock, $0.0001 par value
Percent of class owned
0.3%
Calidi Biotherapeutics common stock
Sole voting power
20,000 shares
Shares with sole voting authority
Sole dispositive power
20,000 shares
Shares the filer alone can dispose of
Event date
March 31, 2026
Date triggering Schedule 13D filing
Key Terms
beneficially owned, sole voting power, sole dispositive power, Schedule 13D, +1 more
5 terms
beneficially owned financial
"11Aggregate amount beneficially owned by each reporting person 20,000.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power financial
"7 | Sole Voting Power 20,000.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"9 | Sole Dispositive Power 20,000.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13D regulatory
"This relates to the disposition of securities by the Reporting Person."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
percent of class financial
"13Percent of class represented by amount in Row (11) 0.3 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Calidi Biotherapeutics (CLDI) does Ognian Anguelov Gavrilov report?
He reports beneficial ownership of 0.3% of Calidi Biotherapeutics’ common stock. This stake corresponds to 20,000 shares with sole voting and dispositive power, as disclosed in the Schedule 13D filing following prior share dispositions.
What is the purpose of the Schedule 13D filed for Calidi Biotherapeutics (CLDI)?
The Schedule 13D updates ownership after dispositions of Calidi Biotherapeutics shares. It reports that the filer now holds about 0.3% of the outstanding shares and currently has no specific plans for major corporate actions involving the company.
Does the Calidi Biotherapeutics (CLDI) filer plan any corporate actions?
The filer states he has no current plans or proposals for actions such as mergers, control changes, or major restructurings. He may still acquire or dispose of Calidi Biotherapeutics securities over time, depending on market conditions and other factors.
When did the reportable ownership change occur for Calidi Biotherapeutics (CLDI)?
The date of the event requiring the Schedule 13D filing is March 31, 2026. As of that date, the reporting person’s beneficial ownership was 20,000 shares, or approximately 0.3% of Calidi Biotherapeutics’ outstanding common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
